| **Chemical-outcome pair** | **Odds ratio [95% CI]** | **I²% [95% CI]** | **p value** |
| --- | --- | --- | --- |
| PFDA - Neoplasms | 1.25 [0.80 to 1.94] | 84.4 [0.0 to 98.3] | 0.1017 |
| PFDA - Perinatal period | 1.01 [0.82 to 1.26] | 12.4 [0.0 to 82.2] | 0.6012 |
| PFDA - Pregnancy or childbirth | 1.04 [0.88 to 1.21] | 25.9 [0.0 to 81.0] | 0.4813 |
| PFHpA - Pregnancy or childbirth | 0.95 [0.69 to 1.30] | 0.0 [0.0 to 18.9] | 0.2818 |
| PFHxS - Diseases of the circulatory system | 1.03 [1.00 to 1.06] | 57.2 [43.3 to 67.7] | 0.0495 |
| PFHxS - Endocrine diseases | 0.99 [0.78 to 1.26] | 51.9 [0.0 to 99.9] | 0.8005 |
| PFHxS - Neoplasms | 1.19 [0.73 to 1.96] | 96.6 [0.0 to 99.9] | 0.3367 |
| PFHxS - Neurodevelopmental disorders | 0.97 [0.78 to 1.21] | 74.7 [0.0 to 100.0] | 0.3750 |
| PFHxS - Perinatal period | 0.98 [0.95 to 1.02] | 13.9 [0.0 to 45.1] | 0.1567 |
| PFHxS - Pregnancy or childbirth | 1.04 [0.98 to 1.10] | 34.7 [0.0 to 62.7] | 0.1439 |
| PFNA - Diseases of the circulatory system | 1.09 [1.02 to 1.16] | 45.4 [0.0 to 89.9] | 0.0285 |
| PFNA - Endocrine diseases | 1.19 [0.47 to 3.04] | 61.6 [0.0 to 100.0] | 0.2506 |
| PFNA - Neoplasms | 0.92 [0.66 to 1.28] | 94.7 [0.0 to 99.9] | 0.4149 |
| PFNA - Neurodevelopmental disorders | 1.00 [0.21 to 4.78] | 25.8 [0.0 to 99.1] | 0.9853 |
| PFNA - Perinatal period | 1.13 [1.00 to 1.28] | 45.6 [0.0 to 75.0] | 0.0482 |
| PFNA - Pregnancy or childbirth | 1.02 [0.87 to 1.19] | 21.4 [0.0 to 73.4] | 0.7480 |
| PFOA - Diseases of the circulatory system | 1.13 [1.05 to 1.23] | 82.4 [41.2 to 94.7] | 0.0249 |
| PFOA - Endocrine diseases | 1.24 [0.65 to 2.38] | 60.1 [0.0 to 87.0] | 0.2444 |
| PFOA - Neoplasms | 1.10 [0.79 to 1.52] | 89.2 [27.1 to 98.4] | 0.3781 |
| PFOA - Neurodevelopmental disorders | 0.98 [0.96 to 1.00] | 60.6 [0.0 to 100.0] | 0.0469 |
| PFOA - Perinatal period | 0.99 [0.87 to 1.12] | 35.9 [0.0 to 59.3] | 0.7450 |
| PFOA - Pregnancy or childbirth | 1.10 [0.98 to 1.24] | 31.3 [0.0 to 60.6] | 0.0716 |
| PFOS - Diseases of the circulatory system | 1.18 [1.01 to 1.39] | 88.7 [39.6 to 97.9] | 0.0466 |
| PFOS - Endocrine diseases | 1.07 [0.19 to 5.89] | 71.2 [0.0 to 99.6] | 0.7058 |
| PFOS - Neoplasms | 1.06 [0.90 to 1.25] | 94.2 [0.0 to 99.8] | 0.3102 |
| PFOS - Neurodevelopmental disorders | 0.98 [0.80 to 1.20] | 49.8 [0.0 to 89.8] | 0.4324 |
| PFOS - Perinatal period | 1.19 [0.88 to 1.60] | 65.8 [31.2 to 83.0] | 0.1501 |
| PFOS - Pregnancy or childbirth | 1.05 [0.97 to 1.13] | 22.6 [6.1 to 36.2] | 0.1323 |
| PFUnDA - Neoplasms | 0.90 [0.32 to 2.52] | 78.6 [0.0 to 96.3] | 0.4152 |
| PFUnDA - Perinatal period | 1.08 [0.06 to 19.84] | 14.6 [0.0 to 74.9] | 0.7963 |
| PFUnDA - Pregnancy or childbirth | 0.87 [0.81 to 0.94] | 16.5 [0.0 to 91.0] | 0.0179 |